You searched for "ranibizumab"
Ranibizumab versus laser in diabetic macular oedema (LUCIDATE study)
1 October 2014
| Efrosini Papagiannuli
|
Retina / Uvea / Vitreous
The aim of this study was to compare the functional and structural effects of Ranibizumab versus macular laser treatment in patients with diabetic macular oedema. It was a single centre, prospective, randomised, single masked clinical trial spanning a 48 week...
Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...Short-term outcome after intravitreal ranibizumab injections for ROP
This is an interventional case series study of three premature babies (six eyes) with high risk prethreshold or threshold retinopathy of prematurity (ROP) with plus disease that received intravitreal ranibizumab injections for ROP. All infants received intravitreal ranibizumab injections of...Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD
5 June 2020
| Jonathan Chan
|
Retina / Uvea / Vitreous
|
clinical trial, degeneration, imaging, macula, neovascularisation
This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
1 October 2018
| Jonathan Chan
|
Retina / Uvea / Vitreous
|
Age related macular degeneration, aflibercept, anti-VEGF therapy, ranibizumab
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
Macula re-attachment following intravitreal ranibizumab in rhegmatogenous retinal detachment
Ranibizumab (Lucentis) is a vascular endothelial growth factor inhibitor (anti-VEGF) used for treatment of choroidal neovascular membrane [1]. We report a case where macula off inferior rhegmatogenous retinal detachment was misdiagnosed as wet age-related macular degeneration (AMD) and three intravitreal...Microvasculature changes of mCNV after ranibizumab treatment using OCTA
4 February 2021
| Sofia Rokerya
|
Retina / Uvea / Vitreous
|
Myopic choroidal neovascularization, Optical coherence tomography angiography, Pathologic myopia
In this study the authors aim to evaluate the vascular changes of myopic choroidal neovascularisation (mCNV) after ranibizumab treatment using optical coherence tomography-angiography (OCTA). The 3×3 OCTA en face images were analysed for the absence / presence of mCNV, CNV...
Detection of antiranibizumab antibodies in exudative AMD
1 December 2014
| Sofia Rokerya
|
Retina / Uvea / Vitreous
In this study the authors aimed to detect immune response to ranibizumab treatment in wet age-related macular degeneration (AMD). An ELISA was employed to quantify the anti-ranibizumab titre which was compared against the control anti-abciximab titre. Titres of anti-ranibizumab antibodies...
Type 3 CNV and anti-VEGF
1 February 2019
| Saruban Pasu
|
Retina / Uvea / Vitreous
The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...
Lucentis for pseudophakic CMO
1 October 2015
| Saruban Pasu
|
Retina / Uvea / Vitreous
|
Cataract, Irvine-Gass syndrome, cystoid macular edema, phacoemulsification, ranibizumab
Pseudophakic cystoid macular oedema (CMO) develops angiographically in up to 20-30% after uneventful phacoemulsification. This study aimed to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic CMO after cataract surgery. Seven eyes were included in...
Systemic pharmacology of intravitreal anti-VEGF
1 April 2018
| Saruban Pasu
|
Retina / Uvea / Vitreous
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Subfoveal choroidal thickness and PCV
1 April 2018
| Saruban Pasu
|
Retina / Uvea / Vitreous
This report studies the prognostic factors for visual improvement and the need for additional treatments at one year after the initial combination therapy of intravitreal ranibizumab injection or intravitreal aflibercept injection followed by PDT in eyes with PCV. Fifty-six eyes...